›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:SafeSEQ AML MRD Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sysmex CorpType:
Laboratory Developed Test
Related tests:
By offering reliable detection of molecular MRD with 50 to 100 times greater sensitivity versus 'pan-heme' NGS tests, the Plasma-SeqSensei AML MRD test will help accelerate clinical development of novel therapeutics and, ultimately, provide oncologists with more reliable information on which to base important decisions for their AML patients.
Cancer:
Acute Myelogenous Leukemia
Gene:
BCOR (BCL6 Corepressor), BRAF (B-raf proto-oncogene), CEBPA (CCAAT Enhancer Binding Protein Alpha), FLT3 (Fms-related tyrosine kinase 3), GATA2 (GATA Binding Protein 2), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
See More ...
BCOR (BCL6 Corepressor), BRAF (B-raf proto-oncogene), CEBPA (CCAAT Enhancer Binding Protein Alpha), FLT3 (Fms-related tyrosine kinase 3), GATA2 (GATA Binding Protein 2), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK2 (Janus kinase 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), NPM1 (Nucleophosmin 1), NRAS (Neuroblastoma RAS viral oncogene homolog), SETBP1 (SET Binding Protein 1), SF3B1 (Splicing Factor 3b Subunit 1), SRSF2 (Serine and arginine rich splicing factor 2), TP53 (Tumor protein P53), U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
Method:
Next-Generation Sequencing